Market Cap 41.53M
Revenue (ttm) 0.00
Net Income (ttm) -75.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.38
Volume 1,478,700
Avg Vol 3,705,200
Day's Range N/A - N/A
Shares Out 44.42M
Stochastic %K 6%
Beta 0.48
Analysts Sell
Price Target $8.67

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 619 3990
Address:
111 S. Wood Avenue, Unit #100, Iselin, United States
Bennyman369
Bennyman369 Sep. 10 at 1:52 AM
0 · Reply
AnalystLLM
AnalystLLM Sep. 10 at 12:42 AM
$OTLK take your time
0 · Reply
SteelerJon
SteelerJon Sep. 9 at 10:26 PM
$OTLK I apologize I should have provided both sources in ChatGPT…in new to it and realized they were there. Here is second source. I hadn’t seen these and found them both informative. https://www.ophthalmologytimes.com/view/fda-issues-complete-response-letter-to-outlook-therapeutics-for-resubmitted-bla-for-ons-5010?utm_source=chatgpt.com
2 · Reply
Jojototo
Jojototo Sep. 9 at 10:19 PM
$OTLK thanks for the source that clarify ur earlier post thank you
0 · Reply
SteelerJon
SteelerJon Sep. 9 at 10:04 PM
$OTLK https://glance.eyesoneyecare.com/stories/2025-09-02/outlook-therapeutics-receives-second-fda-crl-over-wet-amd-bla/?utm_source=chatgpt.com
0 · Reply
SteelerJon
SteelerJon Sep. 9 at 9:36 PM
$OTLK From an AI source: In response to the FDA's Complete Response Letter (CRL) issued on August 28, 2025, Outlook Therapeutics (OTLK) has been advised to provide additional confirmatory evidence of efficacy to support its Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) in the treatment of wet age-related macular degeneration (AMD). The CRL cited a lack of substantial evidence of effectiveness, specifically noting that ONS-5010 did not meet its primary efficacy endpoint in the NORSE EIGHT trial. *The FDA has indicated that additional efficacy data could be derived from the NORSE TWO trial, which demonstrated statistically significant and clinically relevant results, including a 41.7% rate of patients gaining at least 15 letters in best-corrected visual acuity (BCVA) Eyes On Eyecare. This trial compared ONS-5010 to ranibizumab (Lucentis) and met both its primary and secondary endpoints with high statistical significance (p = 0.0052)
2 · Reply
Jojototo
Jojototo Sep. 9 at 9:29 PM
$OTLK so someone made a good point on reddit that otlk could have a possibility of a merger with MS Pharma, so probably higher. Because there more to it then just the CEO flying to Paris for a 5-minute presentation at a 6 hour conference in a country they haven't commercialized. Do you think a merger if it happens will hurt it short term because they will be paying a premium to take over the company debt? Thoughts???
1 · Reply
updownsides
updownsides Sep. 9 at 9:16 PM
$OTLK You call yourself Mr. Stockpicker? Please stay out of anything I own. Kiss if death.
0 · Reply
SteelerJon
SteelerJon Sep. 9 at 8:38 PM
$OTLK Great day…holding strong.😎🏦🏦
1 · Reply
SteelerJon
SteelerJon Sep. 9 at 7:48 PM
$OTLK Yeah…enough going on here trying to get our product approved by FDA, continuing EU/UK rollout, market test of world, etc…. Crypto is probably not in the cards near/term or ever. They are tight on operating capital….they can’t invest in crypto. Let’s get our business taken care of….first. 😎🏦🏦
1 · Reply
Latest News on OTLK
Outlook Therapeutics Requests Type A Meeting with FDA

Sep 2, 2025, 8:35 AM EDT - 7 days ago

Outlook Therapeutics Requests Type A Meeting with FDA


FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 11:15 AM EDT - 12 days ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time


Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

Jan 16, 2025, 12:09 PM EST - 8 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS


Top 3 Health Care Stocks That Could Blast Off This Month

Jan 6, 2025, 7:19 AM EST - 8 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT


Outlook Therapeutics® Streamlines Operations

Dec 13, 2024, 4:30 PM EST - 9 months ago

Outlook Therapeutics® Streamlines Operations


Outlook Therapeutics® Announces Executive Leadership Transition

Dec 3, 2024, 4:30 PM EST - 10 months ago

Outlook Therapeutics® Announces Executive Leadership Transition


Outlook Therapeutics: Worth A Good Strong Look After CRL

Jun 13, 2024, 5:22 PM EDT - 1 year ago

Outlook Therapeutics: Worth A Good Strong Look After CRL


Bennyman369
Bennyman369 Sep. 10 at 1:52 AM
0 · Reply
AnalystLLM
AnalystLLM Sep. 10 at 12:42 AM
$OTLK take your time
0 · Reply
SteelerJon
SteelerJon Sep. 9 at 10:26 PM
$OTLK I apologize I should have provided both sources in ChatGPT…in new to it and realized they were there. Here is second source. I hadn’t seen these and found them both informative. https://www.ophthalmologytimes.com/view/fda-issues-complete-response-letter-to-outlook-therapeutics-for-resubmitted-bla-for-ons-5010?utm_source=chatgpt.com
2 · Reply
Jojototo
Jojototo Sep. 9 at 10:19 PM
$OTLK thanks for the source that clarify ur earlier post thank you
0 · Reply
SteelerJon
SteelerJon Sep. 9 at 10:04 PM
$OTLK https://glance.eyesoneyecare.com/stories/2025-09-02/outlook-therapeutics-receives-second-fda-crl-over-wet-amd-bla/?utm_source=chatgpt.com
0 · Reply
SteelerJon
SteelerJon Sep. 9 at 9:36 PM
$OTLK From an AI source: In response to the FDA's Complete Response Letter (CRL) issued on August 28, 2025, Outlook Therapeutics (OTLK) has been advised to provide additional confirmatory evidence of efficacy to support its Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) in the treatment of wet age-related macular degeneration (AMD). The CRL cited a lack of substantial evidence of effectiveness, specifically noting that ONS-5010 did not meet its primary efficacy endpoint in the NORSE EIGHT trial. *The FDA has indicated that additional efficacy data could be derived from the NORSE TWO trial, which demonstrated statistically significant and clinically relevant results, including a 41.7% rate of patients gaining at least 15 letters in best-corrected visual acuity (BCVA) Eyes On Eyecare. This trial compared ONS-5010 to ranibizumab (Lucentis) and met both its primary and secondary endpoints with high statistical significance (p = 0.0052)
2 · Reply
Jojototo
Jojototo Sep. 9 at 9:29 PM
$OTLK so someone made a good point on reddit that otlk could have a possibility of a merger with MS Pharma, so probably higher. Because there more to it then just the CEO flying to Paris for a 5-minute presentation at a 6 hour conference in a country they haven't commercialized. Do you think a merger if it happens will hurt it short term because they will be paying a premium to take over the company debt? Thoughts???
1 · Reply
updownsides
updownsides Sep. 9 at 9:16 PM
$OTLK You call yourself Mr. Stockpicker? Please stay out of anything I own. Kiss if death.
0 · Reply
SteelerJon
SteelerJon Sep. 9 at 8:38 PM
$OTLK Great day…holding strong.😎🏦🏦
1 · Reply
SteelerJon
SteelerJon Sep. 9 at 7:48 PM
$OTLK Yeah…enough going on here trying to get our product approved by FDA, continuing EU/UK rollout, market test of world, etc…. Crypto is probably not in the cards near/term or ever. They are tight on operating capital….they can’t invest in crypto. Let’s get our business taken care of….first. 😎🏦🏦
1 · Reply
Jojototo
Jojototo Sep. 9 at 7:39 PM
$OTLK pr crypto news that seen to be working for most of these stock to regain compliance in double and triple digits🤕😤
1 · Reply
nacho217
nacho217 Sep. 9 at 6:03 PM
$OTLK Er about to come 10-11 Oct with Numbers of a full quarter sales in UK & Germany, but before we might know about Type A meeting Schedule.EU.
2 · Reply
SilentJoker34
SilentJoker34 Sep. 9 at 5:43 PM
$OTLK Chillin 😎 🇺🇲🧐
0 · Reply
Britbox
Britbox Sep. 9 at 5:34 PM
$OTLK so correct me if I am wrong, but once request for type a meeting has been made, FDA has 10 days to respond? That would put response by end of this week.
3 · Reply
HarveySpecter20
HarveySpecter20 Sep. 9 at 3:48 PM
$OTLK hahaha I remember when this BobTheNewbie guy claimed to be bullish but kept bashing this stock for no reason, so pathetic. Who are they trying to fool, everybody knows that every ST Board has certain 🪳🪳🪳 that are just bashing for no reason. Their parents must be proud 😂😂
1 · Reply
NeurNet
NeurNet Sep. 9 at 3:36 PM
$OTLK @Ajfadogg I'm only reading the post now. You had the courage to express my deepest personal conviction out loud. And you add a few words explaining, quite rightly... that the current context is 100% favorable to it. Your message is remarkable. (That's why I'm responding to it here on the front page.) By the way... I sometimes talk about... 'robots'... It's undeniable... grotesque, even. But it's VERY far from free. Only specialized digital marketing agencies can achieve this...! To stay "positive", let's take a step back... 'Corruption'... yes, that's likely to create a negative feeling, but Mr. Bob JAHR has clearly seen other things in his career. On the other hand... (the "positive" & encouraging" aspect..): No one would attack OTLK like this if OTLK had no chance of "reshuffling the cards" in any market with the price argument, among other things.. I mean... NO ONE spends that much money attacking a LOSER..!!!! ALL THESE ATTACKS COULD BE A BIG CATALYST.
1 · Reply
AnalystLLM
AnalystLLM Sep. 9 at 3:20 PM
$OTLK 1/1/2026 $10
1 · Reply
G101SPM
G101SPM Sep. 9 at 3:17 PM
G101SPM 8/26/2025, 2:59:43 PM $OTLK $2.71 bid. SELL/TAKE PROFIT on entire long position / based on compromised SPM tag. DAC (dollar average cost includes partial SELLS at a profit to reduce cost to zero / last $2.19 (8.14.25).
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:05 PM
G101SPM 8/14/2025, 1:27:09 PM $OTLK $2.19 ask. BUY/ADD 10X to long position carries SPM 87.95 tag to $7.00 in midterm. *DAC (dollar average cost does not include this trade). ... from ARCHIVES prior partial SELLS at a profit reduce net cost to zero. https://stocktwits.com/G101SPM/message/619557846 https://stocktwits.com/G101SPM/message/598943580 https://stocktwits.com/G101SPM/message/594258883
0 · Reply
Britbox
Britbox Sep. 9 at 2:53 PM
$OTLK it’s so crazy to think we are at PRE RS levels again!! Holy moly
2 · Reply
Alfadogg
Alfadogg Sep. 9 at 2:31 PM
$OTLK Let me get this straight. OTLK has a great product that is approved in all of Europe….450M ppl….more than North America….that saves governments lots of money….and helps lots of ppl with a safer, cheaper solution to Wet AMD….and a marketplace that is growing….and a “strategic agreement” with the 10th largest corporation in the world…but we can’t properly commercialize and our stock price is laughable? Do I have this all correct???
2 · Reply
BobTheNewbie
BobTheNewbie Sep. 9 at 2:14 PM
$OTLK u lala , don't wanna go up , but there are lots of good news , waiting for sales data from zimbabwe
1 · Reply